Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012
(firmenpresse) - SAN FRANCISCO, CA and TOKYO -- (Marketwire) -- 05/18/12 -- Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced that six abstracts related to enzalutamide (formerly MDV3100) will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 -5, 2012.
(Abstract #4519): Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor
Saturday, June 2 from 8:30 a.m. - 8:45 a.m.
Presenter: Johann S. De Bono, MB, ChB, FRCP, MSc, PhD
Clinical Science Symposium: New Paradigms for Hormone Therapy in Prostate Cancer Location: E Arie Crown Theater
(Abstract #564 Poster #4G): Effect of MDV3100, an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/AR+) breast cancer xenografts
Saturday, June 2 from 8:00 a.m. to noon
Author: Anthony D. Elias, MD
General Poster Session: Breast Cancer
Location: S Hall A2
(Abstract #TPS668 / Poster #18B): MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer
Saturday, June 2 from 8:00 a.m. to noon
Author: Anthony D. Elias, MD
General Poster Session: Breast Cancer
Location: S Hall A2
(Abstract #TPS4695 / Poster #16F): A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer
Sunday, June 3 from 8:00 a.m. to noon
Author: Robert B. Montgomery, MD
General Poster Session: Genitourinary Cancer
Location: S Hall A2
(Abstract #TPS4698 / Poster #17A): TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC)
Sunday, June 3 from 8:00 a.m. to noon
Author: Edwina S. Baskin-Bey, MD
General Poster Session: Genitourinary Cancer
Location: S Hall A2
(Abstract #3072 / Poster #16F): Effect of MDV3100, a novel androgen receptor signaling inhibitor, on cell proliferation and tumor size in an apocrine breast cancer xenograft model
Monday, June 4 from 8:00 a.m. - noon
Author: Sebastián Bernales, PhD
General Poster Session: Developmental Therapeutics
Location: S Hall A2
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug enzalutamide in Phase 3 development to treat advanced prostate cancer and in Phase 1 development to treat breast cancer. For more information, please visit us at .
Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to becoming a global category leader in Oncology, and has several oncology compounds in development in addition to enzalutamide. For more information on Astellas Pharma Inc., please visit our website at .
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101
Anne Bowdidge
Senior Director, Investor Relations
(650) 218-6900
Jenny Kite
Corporate Communications
(847) 317-5405
Mike Beyer
Sam Brown, Inc (media for both companies)
(773) 463-4211
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2012 - 11:00 Uhr
Sprache: Deutsch
News-ID 148032
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA and TOKYO
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
MDVN (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
